Report : Middle East & Africa Pharmaceutical Excipients Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Bioresorbable Polymers, and Lipids and Liposome-Based Formulation; Oleochemicals; Sugars; Cellulose; Starches; Petrochemicals; Plant Proteins and Polyols and Cyclodextrins; Inorganic Chemicals; and Others), Clinical Indication (Cancer, Metabolic, Infectious Diseases, Dental, Ophthalmic, Gene Therapies, and Others), Functionality (Coloring Agent and Coating Agent, Sweetener and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled-Release, Antioxidant and Oil, Tablet Filler and Diluents, Binders and Compression Aids and Granulating Agents, and Others), Application (Parenteral, Oral Formulations and Tablets, Capsules, Liquid and Injectables, Physicochemical Excipient-Container Interactions in Prefilled Syringes, Nutraceuticals and OTC, Topical, and Others), and End User (Biopharma Industries, Pharma Industries, Animal Health, and Others)
At 5.1% CAGR, the Middle East & Africa Pharmaceutical Excipients Market is speculated to be worth US$ 336.74 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Middle East & Africa pharmaceutical excipients market was valued at US$ 249.21 million in 2022 and is expected to reach US$ 336.74 million by 2028, registering a CAGR of 5.1% from 2022 to 2028. Use of nanotechnology to improve excipients capabilities and rising demand and emphasis on co-processed excipients are the critical factors attributed to the Middle East & Africa pharmaceutical excipients market expansion.
Nano-delivery systems and nanomedicine are new and rapidly growing fields where nanoscale materials are used to deliver therapeutic agents to targeted sites or as diagnostic tools. Nanotechnology provides several advantages in treating chronic human diseases through site-specific and selective delivery of accurate medicines. NADDS face challenges in their production and manufacture. During the manufacturing of NADDS, the process has the potential to convert the excipients into nano-excipients. Nano-excipients have enhanced properties compared to excipients. Nano-excipients are easily transported through biological membranes. Also, they can easily get absorbed into the blood and delivered to the targeted tissue and cell. Nano-excipients stay in the circulatory system for a prolonged period and release the amalgamated drugs as per the specified dose. The efficient production of NADDS includes a detailed understanding of the physicochemical properties and functionality of the excipients. Thus, nanotechnology excipients would witness intensive scientific investigations in the coming years, as they can contribute unique functionality to drug products. This increase in use of nanotechnology for development of nano-excipients and in pharmaceutical drug production is responsible for growth of the Middle East & Africa pharmaceutical excipients market.
On the contrary, cost and time-intensive drug development process hurdles the growth of Middle East & Africa pharmaceutical excipients market.
Based on type, the Middle East & Africa pharmaceutical excipients market is segmented into bioresorbable polymers & lipids & liposome-based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant protein & polyols & cyclodextrins, inorganic chemicals, and others. The inorganic chemicals segment held 24.5% market share in 2022, amassing US$ 62.78 million. It is projected to garner US$ 81.43 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on clinical indication, the Middle East & Africa pharmaceutical excipients market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others. The cancer segment held 31.1% market share in 2022, amassing US$ 77.43 million. It is projected to garner US$ 102.03 million by 2028 to expand at 4.7% CAGR during 2022–2028.
Based on functionality, the Middle East & Africa pharmaceutical excipients market is segmented into coloring agent & coating agents, sweetener & flavoring agents, suspending & viscosity agents, preservative & controlled-release, antioxidant & oil, tablet filler & diluents, binders & compression aids & granulating agents, emulsifiers, and others. The tablet filler and diluents segment held 28.9% market share in 2022, amassing US$ 71.94 million. It is projected to garner US$ 101.95 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on application, the Middle East & Africa pharmaceutical excipients market is segmented into parenteral, orals formulations & tablets, capsules, liquid & injectable, physicochemical excipient container interactions in prefilled syringes, nutraceuticals & OTC, topical, and others. The orals formulations & tablets segment held 45.6% market share in 2022, amassing US$ 113.71 million. It is projected to garner US$ 158.23 million by 2028 to expand at 5.7% CAGR during 2022–2028.
Based on end user, the Middle East & Africa pharmaceutical excipients market is segmented into biopharma industries, pharma industries, animal health, and others. The pharma industries segment held 43.3% market share in 2022, amassing US$ 107.81 million. It is projected to garner US$ 143.87 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on country, the Middle East & Africa pharmaceutical excipients market is segmented into Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 34.0% market share in 2022. It was assessed at US$ 84.61 million in 2022 and is likely to hit US$ 112.30 million by 2028, exhibiting a CAGR of 4.8% during the forecast period.
Key players dominating the Middle East & Africa pharmaceutical excipients market are Archer-Daniels-Midland Co, AshLand Inc, Avantor Inc, BASF SE, Evonik Industries AG, JRS PHARMA GmbH & Co. KG, MEGGLE GmbH & Co KG, Roquette Freres SA, The Dow Chemical Co, and The Lubrizol Corp, among others.
- In 2020, Evonik launched RESOMER Precise platform of custom functional excipients to precisely control the release profile of parenteral drug products.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com